PQB Stock Overview
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Pure Biologics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł1.46 |
| 52 Week High | zł3.52 |
| 52 Week Low | zł1.41 |
| Beta | 1.23 |
| 1 Month Change | -10.57% |
| 3 Month Change | -33.67% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -35.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| PQB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.1% | -2.9% | 1.9% |
| 1Y | n/a | -25.4% | 5.9% |
Return vs Industry: Insufficient data to determine how PQB performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how PQB performed against the German Market.
Price Volatility
| PQB volatility | |
|---|---|
| PQB Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PQB's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine PQB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 56 | n/a | purebiologics.com |
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use.
Pure Biologics S.A. Fundamentals Summary
| PQB fundamental statistics | |
|---|---|
| Market cap | €5.78m |
| Earnings (TTM) | -€7.43m |
| Revenue (TTM) | €25.54k |
226.2x
P/S Ratio-0.8x
P/E RatioIs PQB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PQB income statement (TTM) | |
|---|---|
| Revenue | zł109.00k |
| Cost of Revenue | zł4.43m |
| Gross Profit | -zł4.32m |
| Other Expenses | zł27.40m |
| Earnings | -zł31.72m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -9.53 |
| Gross Margin | -3,960.55% |
| Net Profit Margin | -29,097.25% |
| Debt/Equity Ratio | 94.7% |
How did PQB perform over the long term?
See historical performance and comparison